Literature DB >> 19540195

Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-Ras(G13D).

Alessandro Palmioli1, Elena Sacco, Cristina Airoldi, Federica Di Nicolantonio, Annalisa D'Urzo, Senji Shirasawa, Takehiko Sasazuki, Alessandro Di Domizio, Luca De Gioia, Enzo Martegani, Alberto Bardelli, Francesco Peri, Marco Vanoni.   

Abstract

Mutation of RAS genes is a critical event in the pathogenesis of different human tumors and in some developmental disorders. Here we present an arabinose-derived bicyclic compound displaying selective cytotoxicity in human colorectal cancer cells expressing K-Ras(G13D), that shows high intrinsic nucleotide exchange rate. We characterize binding of bicyclic compounds by docking and NMR experiments and their inhibitory activity on GEF-mediated nucleotide exchange on wild-type and mutant Ras proteins. We demonstrate that the in vitro inhibition of Ras nucleotide exchange depends on the molar ratio between Ras and its GEF activator, suggesting that the observed in vivo selective effect may depend on biochemical parameters and actual intracellular concentration of the Ras protein and its regulators.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19540195     DOI: 10.1016/j.bbrc.2009.06.069

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  A systems mechanism for KRAS mutant allele-specific responses to targeted therapy.

Authors:  Thomas McFall; Jolene K Diedrich; Meron Mengistu; Stacy L Littlechild; Kendra V Paskvan; Laura Sisk-Hackworth; James J Moresco; Andrey S Shaw; Edward C Stites
Journal:  Sci Signal       Date:  2019-09-24       Impact factor: 8.192

Review 2.  Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design.

Authors:  Jonathan M L Ostrem; Kevan M Shokat
Journal:  Nat Rev Drug Discov       Date:  2016-07-29       Impact factor: 84.694

3.  KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation.

Authors:  Jia Lu; Asim K Bera; Sudershan Gondi; Kenneth D Westover
Journal:  Biochemistry       Date:  2017-12-28       Impact factor: 3.162

4.  Mathematical Modeling to Study KRAS Mutant-Specific Responses to Pathway Inhibition.

Authors:  Edward C Stites
Journal:  Methods Mol Biol       Date:  2021

5.  Graded inhibition of oncogenic Ras-signaling by multivalent Ras-binding domains.

Authors:  Martin Augsten; Anika Böttcher; Rainer Spanbroek; Ignacio Rubio; Karlheinz Friedrich
Journal:  Cell Commun Signal       Date:  2014-01-02       Impact factor: 5.712

Review 6.  Towards a Universal Approach Based on Omics Technologies for the Quality Control of Food.

Authors:  Emanuele Ferri; Andrea Galimberti; Maurizio Casiraghi; Cristina Airoldi; Carlotta Ciaramelli; Alessandro Palmioli; Valerio Mezzasalma; Ilaria Bruni; Massimo Labra
Journal:  Biomed Res Int       Date:  2015-12-13       Impact factor: 3.411

7.  Spiclomazine displays a preferential anti-tumor activity in mutant KRas-driven pancreatic cancer.

Authors:  Xiaoyu Guo; Wenjing Zhao; Zuojia Liu; Jin Wang
Journal:  Oncotarget       Date:  2018-01-08

8.  From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers.

Authors:  Mahsa Saliani; Razieh Jalal; Mohammad Reza Ahmadian
Journal:  Cancer Biol Med       Date:  2019-08       Impact factor: 4.248

Review 9.  Natural Products Attenuating Biosynthesis, Processing, and Activity of Ras Oncoproteins: State of the Art and Future Perspectives.

Authors:  Renata Tisi; Vadim Gaponenko; Marco Vanoni; Elena Sacco
Journal:  Biomolecules       Date:  2020-11-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.